hzVSF-v13

DRUG4 trials

Sponsors

ImmuneMed, Inc.

Conditions

COVID-19Healthy

Phase 1

Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers

CompletedNCT03653208

ImmuneMed, Inc.Healthy

Start: 2018-11-20End: 2020-02-29Updated: 2021-04-27

Phase 2

Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia

CompletedNCT04676971

ImmuneMed, Inc.COVID-19

Start: 2020-12-11End: 2021-10-28Updated: 2021-12-01

Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia

CompletedNCT04679415

ImmuneMed, Inc.COVID-19

Start: 2020-12-17End: 2021-08-19Updated: 2024-02-15

Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia

TerminatedNCT04679350

ImmuneMed, Inc.COVID-19

Start: 2021-03-18End: 2022-12-30Updated: 2024-02-15